Abstract:132 Background: Most recently, there were 3 reports of prospective randomized clinical trials comparing the effects of primary tumor resection (PTR) for multiorgan metastatic colorectal cancer followed by chemotherapy with chemotherapy alone, but the results differed and unconvincing due to the prematurely study termination and research protocol changes. PTR was preferably performed for patients with asymptomatic synchronous unresectable colorectal liver-limited metastases (CRLMs) with conversion therapy purpose, including the CELIM, OLIVIA and our study (J Clin Oncol 2013;31:1931-8). This randomized phase III study investigated the superiority of preoperative chemotherapy prior to PTR for patients with asymptomatic synchronous unresectable CRLMs. Methods: Patients with asymptomatic synchronous unresectable CRLMs were randomly assigned to receive pre-PTR chemotherapy (arm A) or upfront PTR (arm B). Chemotherapy regimens of mFOLFOX6 plus cetuximab, mFOLFOX6 plus bevacizumab or mFOLFOX6 alone were decided according to the RAS genotype. The primary end point was progression-free survival (PFS); secondary end points included overall survival (OS), tumor response, disease control rate (DCR), liver metastases resection rate, surgical complications and chemotherapy toxicity. Results: Between June 2012 and June 2018, a total of 320 patients were randomly assigned to arm A (160 patients) or arm B (160 patients). The cutoff date for survival data was June 2021, the median follow-up time was 36.2 months. Patients were well balanced. For the intention-to-treat population, the median PFS, median OS, and 3-year OS rates were 9.9 months, 28.0 months, and 37.0%, respectively. The median PFS in arm A was significantly improved compared with arm B (10.5 v 9.1 months; hazard ratio [95% CI, 0.60 to 0.95], 0.76; P = 0.013). Patients in arm A also had a significantly better DCR (84.4% v 75.0%; P = 0.037). The median OS was not significantly different (29.4 v 27.2 months; hazard ratio [95% CI, 0.58 to 1.01], 0.77, P = 0.058), and the objective response rates were also not significantly different (53.1% v 45.0%; P = 0.146). The actual resection rate of liver metastases was not significantly different (21.9% v 18.1%; P = 0.402). There were mild morbidities and no 30-day postoperative mortalities in both arms. The rate of complications was not significantly different (37.7% v 30.8%, P = 0.201). The incidence of Clavien–Dindo 3-4 complications also did not reach statistical significance (4.5% v 3.8%, P = 0.759). Overall the observed toxicity was mostly mild. There was no significant difference in the overall incidence of predefined grade 3/4 events (42.2% v 40.4%, P = 0.744). There were no grade 5 events in either arm. Conclusions: For asymptomatic synchronous unresectable CRLMs, Pre-PTR chemotherapy improved the PFS compared with upfront PTR. Clinical trial information: NCT01307878 .

What is the optimal number of neoadjuvant chemotherapy cycles for resectable colorectal liver oligometastases?

From the completion of neoadjuvant chemotherapy to surgery for colorectal cancer liver metastasis: What is the optimal timing?

Efficacy and safety of different cycles of neoadjuvant immunotherapy in resectable non-small cell lung cancer: A systematic review and meta-analysis

Preoperative Chemotherapy Prior to Primary Tumor Resection for Asymptomatic Synchronous Unresectable Colorectal Liver-Limited Metastases: A Multicenter Randomized Controlled Trial.

Survival and Prognostic Factors of Colorectal Liver Metastases after Surgical and Nonsurgical Treatment.

Proposal Of The Optimal Numbers Of Examined And Positive Lymph Nodes To The 8th Edition Of American Joint Committee On Cancer (Ajcc) Staging For 758 Patients With Distal Cholangiocarcinoma

Optimal Surgical Sequence for Colorectal Cancer Liver Metastases Patients Receiving Colorectal Cancer Resection with Simultaneous Liver Metastasis Resection: A Multicentre Retrospective Propensity Score Matching Study.

Effect of Neoadjuvant Chemotherapy in Patients with Resectable Colorectal Liver Metastases.

Oncological outcomes of neoadjuvant chemotherapy in patients with resectable synchronous colorectal liver metastasis: A result from a propensity score matching study

Effect of tumor number on the survival of patients of colorectal cancer liver metastases undergoing hepatic resection

Does the Number of Cycles of Neoadjuvant Therapy Affect the Efficacy of Neoadjuvant Chemoimmunotherapy for Non-Small Cell Lung Cancer in Locally Advanced Stage? Retrospective Experience Based on a Single Center

The optimal number of induction chemotherapy cycles in clinically lymph node‐positive bladder cancer

The role of neoadjuvant chemotherapy for resectable colorectal liver metastases: a systematic review and meta-analysis.

Neoadjuvant Chemotherapy Improves Overall Survival in Resectable Colorectal Liver Metastases Patients with High Clinical Risk Scores-- A Retrospective, Propensity Score Matching Analysis.

Postoperative adjuvant chemotherapy is important for improving long‐term survival in patients with colorectal cancer liver metastases undergoing simultaneous resection

One Cycle of Concurrent Chemotherapy vs. Two Cycles of Concurrent Chemotherapy With Radiation Therapy in Patients With Limited-Stage Small Cell Lung Cancer

Irinotecan- Vs Oxaliplatin-Based Regimens for Neoadjuvant Chemotherapy in Colorectal Liver Metastasis Patients: A Retrospective Study.

Upgraded nomograms for the prediction of complications and survival in patients with colorectal liver metastases treated with neoadjuvant chemotherapy followed by hepatic resection

Prognostic factors in colorectal liver metastases patients with various tumor numbers treated by liver resection: a single-center, retrospective study

Neoadjuvant Immunotherapy for Patients With Microsatellite Instability-High or POLE-Mutated Locally Advanced Colorectal Cancer With Bulky Tumors: New Optimization Strategy

Current landscape of preoperative neoadjuvant therapies for initial resectable colorectal cancer liver metastasis